Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Assets Average (2016 - 2025)

Historic Assets Average for Celldex Therapeutics (CLDX) over the last 15 years, with Q3 2025 value amounting to $670.4 million.

  • Celldex Therapeutics' Assets Average fell 1965.04% to $670.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $670.4 million, marking a year-over-year decrease of 1965.04%. This contributed to the annual value of $629.0 million for FY2024, which is 5371.77% up from last year.
  • Per Celldex Therapeutics' latest filing, its Assets Average stood at $670.4 million for Q3 2025, which was down 1965.04% from $715.9 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Assets Average ranged from a high of $857.2 million in Q2 2024 and a low of $211.8 million during Q2 2021
  • Moreover, its 5-year median value for Assets Average was $413.5 million (2022), whereas its average is $497.4 million.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 2494.47% in 2023, then soared by 18793.31% in 2024.
  • Over the past 5 years, Celldex Therapeutics' Assets Average (Quarter) stood at $452.4 million in 2021, then fell by 20.21% to $361.0 million in 2022, then increased by 3.31% to $372.9 million in 2023, then surged by 116.59% to $807.8 million in 2024, then fell by 17.0% to $670.4 million in 2025.
  • Its Assets Average stands at $670.4 million for Q3 2025, versus $715.9 million for Q2 2025 and $765.9 million for Q1 2025.